Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-02-01
2011-02-01
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000
Reexamination Certificate
active
07879815
ABSTRACT:
The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.
REFERENCES:
patent: 6312662 (2001-11-01), Erion et al.
patent: 6914054 (2005-07-01), Sommadossi et al.
patent: 2004/0181051 (2004-09-01), Storer et al.
patent: 2005/0009737 (2005-01-01), Clark
patent: 2005/0009775 (2005-01-01), Howes et al.
patent: 2007/0197463 (2007-08-01), Chun et al.
patent: WO 2006/063149 (2006-06-01), None
patent: WO 2006/121820 (2006-11-01), None
Bartenschlager, R. “Candidate Targets for Hepatitis C Virus-Specific Antiviral Therapy”, Intervirology, 1997, vol. 40, pp. 378-393.
Crabb, C. “Hard-Won Advances Spark Excitement About Hepatitis C”, Science, 2001, vol. 294, pp. 506-507.
Dymock, B. “Emerging therapies for hepatitis C virus infection”, Emerging Drugs, 2001, vol. 6, pp. 13-42.
Dymock, B. et al. “Novel approaches to the treatment of hepatitis C virus infection”, Antiviral Chemistry & Chemotherapy, 2000, vol. 11, pp. 79-96.
Eldrup, A. et al. “Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase”, J. Med. Chem., 2004, vol. 47, pp. 2283-2295.
Hoffmann, P. et al. “Recent patents on experimental therapy for hepatitis C virus infection (1999-2002)”, Expert. Opin. Ther. Patents, 2003, vol. 13, pp. 1707-1723.
Ishi, K. et al. “Expression of Hepatitis C Virus NS5B Protein: Characterization if Its RNA Polymerase Activity and RNA Binding”, Hepatology, 1999, vol. 29, pp. 1227-1235.
Lauer, G. et al. “Hepatitis C Virus Infection”, New England Journal of Medicine, 2001, vol. 345, pp. 41-52.
Lohmann, V. et al. “Biochemical and Kinetic Analyses of NS5B RNA-Dependent RNA Polymerase of the Hepatitis C Virus”, Virology, 1998, vol. 249, pp. 108-118.
McGuigan, C. et al. “Application of Phosphoramidate Pronucleotide Technology to Abacavir Leads to a Significant Enhancement of Antiviral Potency”, Journal of Medicinal Chemistry, 2005, vol. 48, pp. 3504-3515.
Moradpour, D. et al. “Current and evolving therapies for hepatitis C”, European Journal of Gastroenterology & Hepatology, 1999, vol. 11, pp. 1199-1202.
Rosen, H. et al. “Hepatitis C virus: current understanding and prospects for future therapies”, Molecular Medicine Today, 1999, vol. 5, pp. 393-399.
Siccardi, D. et al. Stereoselective and Concentration-Dependent Polarized Epithelial Permeability of a Series of Phosphoramidate Triester Prodrugs of d4T: An in Vitro Study in Caco-2 and Madin-Darby Canine Kidney Cell Monolayers, The Journal of Pharmacology and Experimental Therapeutics, 2003, vol. 307, pp. 1112-1119.
Siddiqui, A. et al. “The Presence of Substituents on the Aryl Moiety of the Aryl Phosphoramidate Derivative of d4T Enhances Anti-HIV Efficacy in Cell Culture: A Structure-Activity Relationship”, Journal of Medicinal Chemistry, 1999, vol. 42, pp. 393-399.
Takamatsu, S. et al. “Convenient Synthesis of Fluorinated Nucleosides with Perfluoroalkanesulfonyl Fluorides”, Nucleosides, Nucleotides & Nucleic Acids, 2002, vol. 21, pp. 849-861.
Uchiyama, M. et al. “O'Selective Phosphorylation of Nucleotides without N-Protection”, Journal of Organic Chemistry, 1993, vol. 58, pp. 373-379.
Walker, M. et al. “Promising candidates for the treatment of chronic hepatitis C”, Expert Opin. Investig. Drugs, 2003, vol. 12, pp. 1269-1280.
Donghi Monica
Gardelli Cristina
Harper Steven
Maccoss Malcolm
Meppen Malte
Durette Philippe L.
Heber Sheldon O.
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
Lewis Patrick T
Merck Sharp & Dohme Corp.
LandOfFree
Nucleoside aryl phosphoramidates for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleoside aryl phosphoramidates for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside aryl phosphoramidates for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2639613